Biden names Dr. Ashish Jha new Covid response coordinator to succeed Jeff Zients

Biden names Dr. Ashish Jha new Covid response coordinator to succeed Jeff Zients


Dr. Ashish Jha is pictured in Providence, RI on Dec. 3, 2020.

Jonathan Wiggs | Boston Globe | Getty Images

President Joe Biden on Thursday named Dr. Ashish Jha as his new Covid-19 response coordinator to succeed Jeff Zients, who served in the role through the delta and omicron surges.

Jha leads Brown University’s School of Public Health and previously headed Harvard’s Global Health Institute. He is a well-known public commentator on how Americans should respond to health risks in the pandemic.

Jha, in a Twitter post, cautioned that the pandemic is not over and the U.S. needs to prepare for future variants and surges by keeping schools and workplaces safe.

New Covid infections in the U.S. have plunged more than 90% since the peak of an unprecedented omicron surge in January, according to data from Johns Hopkins University. Hospitalizations are down 89% from the omicron peak, according to the Centers for Disease Control and Prevention. However, infections are rising again in major European nations, such as the U.K. and Germany, and China is battling its worst outbreak since 2020.

Zients has led the White House Covid response team for 14 months and has held countless public briefings on the changing state of pandemic. Biden praised Zients’ work in a statement, noting that most adults have become fully vaccinated during his tenure. More than 75% of adults in the U.S. have received two doses of a vaccine, according to CDC data.

“The progress that he and his team have made is stunning and even more important consequential. Lives have been saved,” Biden said in a statement

CNBC Health & Science

Read CNBC’s latest global coverage of the Covid pandemic:



Source

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here
Health

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here

Wall Street is optimistic that Olema Pharmaceutical could be developing the next major breakthrough breast cancer treatment. Earlier this month, the company announced promising clinical data for its lead candidate palazestrant, an oral medication that is being evaluated in several trials for estrogen receptor-positive, or ER+, breast cancer. Shares of the clinical-stage biopharmaceutical company are up […]

Read More
This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’
Health

This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’

It’s been a stellar few months for shares of San Francisco-based biotech company Rigel Pharmaceuticals, which has approved treatments for rheumatology and oncology — as well as potential new drugs in the pipeline. The stock has jumped about 50% in just the last three months, earning it a spot on CNBC’s list of top performing […]

Read More
We’re raising our Eli Lilly price target — what a difference a quarter makes
Health

We’re raising our Eli Lilly price target — what a difference a quarter makes

Eli Lilly shares jumped Thursday after the drugmaker posted a strong third quarter, driven by sales of its popular GLP-1 medications. The company also raised its full-year sales outlook for the second time in a row, inspiring confidence in the trajectory of the franchise. Revenue in the three months ended Sept. 30 jumped 54% year […]

Read More